摘要
目的评价双歧杆菌三联活菌制剂治疗急慢性腹泻的一临床疗效。方法检索中国知网、万方、维普、Pubmed、EMbase、webofScience数据库，收集2000年1月至2013年12月国内外应用双歧杆菌三联活菌制剂治疗急慢性腹泻的所有随机对照试验（randomized controlled trial，RCT）和前瞻性非随机对照试验（non—randomized controlled trial，non—RCT）。按照纳入与排除标准选择文献、提取资料和评价纳入研究的方法学质量后，采用Cochrane协作网提供的RevMan5．2软件进行Meta分析。结果纳入10个前瞻性non-RCT，共822例患者，其中治疗组（对照组常规用药＋双歧杆菌三联活菌制剂）413例，对照组409例。治疗组的总有效率高于对照组（OR3．18，95％CI2．07～4．89，P〈0．01）；治疗组与对照组治疗急慢性腹泻大便性状好转率差异无统计学意义（OR1．63，95％CI0.70～3．83，P=0．26）；治疗组与对照组治疗急慢性腹泻消化道症状好转率差异无统计学意义（OR1．68，95％CI0．73～3．86，P=0．22）。结论双歧杆菌三联活菌制剂与常规治疗药物联用可以提高急慢性腹泻的总体疗效，相关症状改善情况有待进一步大样本多中心RCT研究进行验证。
Objective To evaluate the clinical therapeutic effect of live combined Bifidobacterium, Lactobacillus and Enterococcus capsules/powder in treating acute or chronic diarrhea by meta analysis. Methods Such databases as China Knowledge Resource Integrated Database, Wanfang Database, Vip Database, Pubmed, Embase and Web of Science were searched to collect all randomized controlled trials （RCTs） and prospective non-randomized controlled trials （non-RCTs） on live combined Bifidobacterium, LactobaciUus and Enterococcus capsules/powder in treating acute or chronic diarrhea. The included time of all studies ranged from January 2000 to December 2013 and the studies were selected according to the inclusion and exclusion criteria. The data were extracted, the methodological quality of the included studies was assessed, and the Meta-analysis was performed with RevmanS.2. Results A total of 10 prospective non-RCTs involving 822 patients were included, including 413 patients from treatment group （Live Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules/Powder plus conventional treatment） and 409 patients from control group （conventional treatment）. The total effective rate of the treatment group was superior to that of the control group （OR 3.18, 9S%CI 2.07- 4.89, P〈0.01）; there was no significant difference in the improvement rate of stool characters between two groups（OR 1.63, 95%CI 0.70-3.83, P=0.26）; there was no significant difference in the improvement rate of digestive tract symptoms between two groups （OR 1.68, 9$%CI 0.73-3.86, P=0.22）. Conclusion Live Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules/Powder combined with conventional drugs can improve the total therapeutic effect on acute or chronic diarrhea; the improvement of relevant symptoms needs to be proved by large sample multicenter RCT research.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2016年第11期1013-1017,共5页
Chinese Journal of Practical Internal Medicine
关键词
双歧杆菌三联活菌制剂
急慢性腹泻
META分析
live combined Bitidobacterium, Lactobacillus and Enterococcus capsules/powder
acute or chronic diarrhea
Meta analysis
